Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
701 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis.
Baur D, Gladstone BP, Burkert F, et al. · Lancet Infect Dis · 2017Meta-Analysis, Systematic Review
- Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ, Miller MA, Mullane KM, et al. · N Engl J Med · 2011Clinical Trial, Phase III, Comparative Study
- Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S, Assi M, Lee C, et al. · Drugs · 2022Randomized Controlled Trial, Clinical Trial, Phase III
- Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
Minkoff NZ, Aslam S, Medina M, et al. · Cochrane Database Syst Rev · 2023Systematic Review, Research Support, N.I.H., Extramural
- Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection : A Randomized Controlled Trial.
Juul FE, Bretthauer M, Johnsen PH, et al. · Ann Intern Med · 2025Equivalence Trial, Multicenter Study
- SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
Feuerstadt P, Louie TJ, Lashner B, et al. · N Engl J Med · 2022Clinical Trial, Phase III, Multicenter Study
- Caloric restriction disrupts the microbiota and colonization resistance.
von Schwartzenberg RJ, Bisanz JE, Lyalina S, et al. · Nature · 2021Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Proton pump inhibitors are not associated with an increased risk of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials.
Floria DE, Obeidat M, Váncsa S, et al. · Gut Microbes · 2025Systematic Review, Meta-Analysis
- Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.
Keating JA, Xu T, Graham MB, et al. · JAMA Netw Open · 2025Randomized Controlled Trial, Clinical Trial, Phase II
- Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis.
Zhao Z, Wu Y, Geng X, et al. · Medicine (Baltimore) · 2024Systematic Review, Meta-Analysis
- Vancomycin Enema in the Treatment of Clostridium difficile Infection.
Fawley J, Napolitano LM · Surg Infect (Larchmt) · 2019Systematic Review
- Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children.
Esmaeilinezhad Z, Ghosh NR, Walsh CM, et al. · Cochrane Database Syst Rev · 2025Meta-Analysis, Systematic Review
- Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.
Goldenberg JZ, Yap C, Lytvyn L, et al. · Cochrane Database Syst Rev · 2017Meta-Analysis, Research Support, Non-U.S. Gov't
- Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial.
Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. · Am J Respir Crit Care Med · 2021Multicenter Study, Randomized Controlled Trial
- Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and network meta-analysis.
Ma Y, Yang JY, Peng X, et al. · J Dig Dis · 2020Systematic Review, Network Meta-Analysis
- VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.
Louie T, Golan Y, Khanna S, et al. · JAMA · 2023Clinical Trial, Phase II, Randomized Controlled Trial
- Duodenal infusion of donor feces for recurrent Clostridium difficile.
van Nood E, Vrieze A, Nieuwdorp M, et al. · N Engl J Med · 2013Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.
Donskey CJ, Dubberke ER, Klein NP, et al. · Clin Infect Dis · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence.
Garey KW, Rose W, Gunter K, et al. · Ann Pharmacother · 2023Systematic Review, Research Support, Non-U.S. Gov't
- Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
Guery B, Menichetti F, Anttila VJ, et al. · Lancet Infect Dis · 2018Clinical Trial, Phase III, Clinical Trial, Phase IV
- Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile.
Tixier EN, Verheyen E, Luo Y, et al. · Dig Dis Sci · 2022Meta-Analysis, Research Support, N.I.H., Extramural
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Cornely OA, Crook DW, Esposito R, et al. · Lancet Infect Dis · 2012Clinical Trial, Phase III, Comparative Study
- Diverting Loop Ileostomy for Clostridium Difficile Colitis: A Systematic Review and Meta-analysis.
Shellito AD, Russell MM · Am Surg · 2020Meta-Analysis, Systematic Review
- Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis.
Pattani R, Palda VA, Hwang SW, et al. · Open Med · 2013Meta-Analysis, Systematic Review
- Does this patient have Clostridioides difficile infection? A systematic review and meta-analysis.
Manzoor F, Manzoor S, Pinto R, et al. · Clin Microbiol Infect · 2023Meta-Analysis, Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.